Correlation between the levels of antibodies against P14 and P14c.

<p>The level of anti-P14 antibodies was highly correlated with the level of antibodies against P14c.</p

Recognition of P14a, P14b and P14c in anti-GBM patients with anti-P14 antibodies.

<p>All sera reacted with P14c exclusively. No serum showed any reactivity to P14a or P14b.</p

Antibody levels against P14c and the peptides with sequential residue substitution by alanine at each position of P14c.

<p>Sera of the 16 anti-GBM patients were detected against each substituted peptides by ELISA. The substitutions at positions 142, 143 and 145 of P14c had significant affect on the antigenicity of P14c (P<0.001).</p

Demographic data, clinical and pathological parameters of anti-GBM patients with anti-P14 antibodies.

<p>n = 16 patients. ANCA, antineutrophil cytoplasmic antibody; MPO, myeloperoxidase; PR3, proteinase 3; GBM, glomerular basement membrane.</p><p>Demographic data, clinical and pathological parameters of anti-GBM patients with anti-P14 antibodies.</p

Sequences of P14 and P14a-c of α3(IV)NC1.

<p>Sequences of P14 and P14a-c of α3(IV)NC1.</p

Sequences and antibody response of the peptides with sequential residue substitution by alanine at each position of P14c.

<p>P, levels of antibodies against each substituted peptide were compared with the levels of anti-P14c antibodies, a P value <0.05 was considered significant; ns, no significance</p><p>Sequences and antibody response of the peptides with sequential residue substitution by alanine at each position of P14c.</p

Correlation between the levels of antibodies against P14 and P14c.

<p>The level of anti-P14 antibodies was highly correlated with the level of antibodies against P14c.</p

Clinical data of patients with anti-GBM disease.

<p>Clinical data of patients with anti-GBM disease.</p